{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:23:46Z","timestamp":1793733826288,"version":"4.6.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ctrv.2013.03.005","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T05:32:10Z","timestamp":1365571930000},"page":"974-984","source":"Crossref","is-referenced-by-count":294,"title":["Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors"],"prefix":"10.1016","volume":"39","author":[{"given":"Anne","family":"Polk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete","family":"Vaage-Nilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Vistisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte L","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2013.03.005_b0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003495-199957040-00003","article-title":"Cardiotoxicity of the antiproliferative compound fluorouracil","volume":"57","author":"Becker","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2013.03.005_b0010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ctrv.2013.03.005_b0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jjco\/hyi071","article-title":"Cardiotoxicity of de Gramont\u2019s regimen: incidence, clinical characteristics and long-term follow-up","volume":"35","author":"Meydan","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2710.2004.00556.x","article-title":"Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion","volume":"29","author":"Ceyhan","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ctrv.2013.03.005_b0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0742-2822.2005.03169.x","article-title":"Ultrasound tissue characterization by integrated backscatter for analyzing fluorouracil induced myocardial damage","volume":"22","author":"Ceyhan","year":"2005","journal-title":"Echocardiography"},{"key":"10.1016\/j.ctrv.2013.03.005_b0030","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jjco\/hyh047","article-title":"Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil\/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers","volume":"34","author":"Oztop","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0035","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/annonc\/mdf108","article-title":"Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil","volume":"13","author":"Van","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000227226","article-title":"Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study","volume":"50","author":"Akhtar","year":"1993","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2013.03.005_b0045","first-page":"1883","article-title":"Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients \u2013 a pilot study","volume":"27","author":"Holubec","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2013.03.005_b0290","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0055","first-page":"887","article-title":"Left ventricular function in colon cancer patients receiving adjuvant fluoro-folate chemotherapy: an echocardiographic study","volume":"7","author":"Balloni","year":"2000","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2013.03.005_b0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0167-8140(88)90296-4","article-title":"Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil","volume":"13","author":"Eskilsson","year":"1988","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0065","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0075","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/1120009X.1990.11739029","article-title":"Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin","volume":"2","author":"Jeremic","year":"1990","journal-title":"J Chemother"},{"issue":"5","key":"10.1016\/j.ctrv.2013.03.005_b0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000331645","article-title":"Clinical and electrocardiography changes in patients treated with capecitabine","volume":"57","author":"Koca","year":"2011","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ctrv.2013.03.005_b0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0090","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1875-9114.1997.tb03748.x","article-title":"Symptomatic cardiotoxicity associated with 5-fluorouracil","volume":"17","author":"Meyer","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ctrv.2013.03.005_b0095","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.ejca.2005.03.027","article-title":"The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)","volume":"41","author":"Ng","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2013.03.005_b0100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1989.7.4.509","article-title":"Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study","volume":"7","author":"Rezkalla","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0105","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12032-009-9226-8","article-title":"5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels","volume":"27","author":"Salepci","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0110","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-Fluorouracil induces arterial vasocontractions","volume":"15","author":"Sudhoff","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000072334","article-title":"High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients","volume":"65","author":"Wacker","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2013.03.005_b0120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1742-1241.2007.01323.x","article-title":"5-fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring","volume":"61","author":"Yilmaz","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ctrv.2013.03.005_b0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mpo.2950190103","article-title":"Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience","volume":"19","author":"Gradishar","year":"1991","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0130","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0135","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/j.1552-4604.1993.tb01943.x","article-title":"Clinical cardiotoxicity of 5-fluorouracil","volume":"33","author":"Keefe","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0140","first-page":"430","article-title":"A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center","volume":"62","author":"Khan","year":"2012","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.ctrv.2013.03.005_b0145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/030089168206800609","article-title":"Cardiac toxicity of 5-fluorouracil: a study on 1083 patients","volume":"68","author":"Labianca","year":"1982","journal-title":"Tumori"},{"key":"10.1016\/j.ctrv.2013.03.005_b0150","first-page":"645","article-title":"Analysis of recovery time indexes in 5-fluorouracil-treated cancer patients","volume":"5","author":"Orditura","year":"1998","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2013.03.005_b0155","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/bmj.1.6112.547","article-title":"Fluorouracil cardiotoxicity","volume":"1","author":"Pottage","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.ctrv.2013.03.005_b0160","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E","article-title":"Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer","volume":"72","author":"Schober","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.03.005_b0165","first-page":"E27","article-title":"Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease","volume":"93","author":"Tsibiribi","year":"2006","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ctrv.2013.03.005_b0170","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9149(00)80079-X","article-title":"5-Fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens","volume":"75","author":"Weidmann","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2008.12.072","article-title":"Clinical implications of the P wave duration and dispersion: relationship between atrial conduction defects and abnormally prolonged and fractionated atrial endocardial electrograms","volume":"134","author":"Centurion","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0180","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijcard.2009.03.023","article-title":"Association of P wave duration and dispersion with the risk for atrial fibrillation: practical considerations in the setting of coronary artery disease","volume":"144","author":"Turgut","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0185","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2009.08.002","article-title":"Electrocardiographic predictors of atrial fibrillation","volume":"158","author":"Perez","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ctrv.2013.03.005_b0190","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.03.005_b0195","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0002-8703(98)70054-7","article-title":"Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease","volume":"135","author":"Stein","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.ctrv.2013.03.005_b0295","first-page":"1","article-title":"Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure","author":"Balion","year":"2006","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"10.1016\/j.ctrv.2013.03.005_b0205","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1515\/cclm.2011.824","article-title":"The prognostic value of N-terminal pro-brain natriuretic peptide in non-ST elevation acute coronary syndromes: a meta-analysis","volume":"50","author":"Zeng","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ctrv.2013.03.005_b0210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.hco.0000240578.05053.f9","article-title":"Integrated backscatter for the assessment of myocardial viability","volume":"21","author":"Yamada","year":"2006","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0215","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0002-8703(96)90390-7","article-title":"Myocardial integrated ultrasonic backscatter in patients with old myocardial infarction: comparison with radionuclide evaluation","volume":"132","author":"Naito","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.ctrv.2013.03.005_b0220","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1536\/jhj.45.937","article-title":"Dipyridamole stress echocardiography and ultrasonic myocardial tissue characterization in predicting myocardial ischemia, in comparison with dipyridamole stress Tc-99m MIBI SPECT myocardial imaging","volume":"45","author":"Onbasili","year":"2004","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.ctrv.2013.03.005_b0225","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.80.3.491","article-title":"Ultrasonic tissue characterization with integrated backscatter. Acute myocardial ischemia, reperfusion, and stunned myocardium in patients","volume":"80","author":"Milunski","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.ctrv.2013.03.005_b0230","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1540-8175.2002.00279.x","article-title":"Use of cyclic variation of integrated backscatter to assess contractile reserve and myocardial viability in chronic ischemic left ventricular dysfunction","volume":"19","author":"Yuda","year":"2002","journal-title":"Echocardiography"},{"key":"10.1016\/j.ctrv.2013.03.005_b0235","first-page":"3028","article-title":"In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.03.005_b0240","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1568011023354146","article-title":"The prodrugs of 5-fluorouracil","volume":"2","author":"Malet-Martino","year":"2002","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"10.1016\/j.ctrv.2013.03.005_b0245","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients","volume":"45","author":"Schuller","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0250","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical pharmacokinetics of capecitabine","volume":"40","author":"Reigner","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ctrv.2013.03.005_b0255","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1345\/aph.10180","article-title":"Recurrent asymptomatic bradycardia episodes after cisplatin infusion","volume":"35","author":"Altundag","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ctrv.2013.03.005_b0260","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/030089168607200215","article-title":"Cardiac arrhythmia: possible complication from treatment with cisplatin","volume":"72","author":"Canobbio","year":"1986","journal-title":"Tumori"},{"key":"10.1016\/j.ctrv.2013.03.005_b0265","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1023\/A:1008231521553","article-title":"Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature","volume":"8","author":"Tassinari","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0270","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1440-1681.2009.05323.x","article-title":"Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress","volume":"37","author":"Ma","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0300","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","article-title":"Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies","volume":"650","author":"El-Awady","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ctrv.2013.03.005_b0280","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/pbc.20804","article-title":"Cisplatin-induced hypomagnesemia and cardiac dysrhythmia","volume":"49","author":"Bashir","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2013.03.005_b0285","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1089\/cbr.2009.0679","article-title":"Resveratrol protects against Cisplatin-induced cardiotoxicity by alleviating oxidative damage","volume":"24","author":"Wang","year":"2009","journal-title":"Cancer Biother Radiopharm"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T17:02:25Z","timestamp":1715187745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737213000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0305737213000686"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.005","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}